CVS Health Corp. Competitive Strategy & SWOT Analysis

The 2024 Aetna Medicare Advantage underwriting loss was the most damaging financial event in CVS Health's recent history. Medicare Advantage plans receive fixed per-member per-month payments from CMS and absorb the risk that actual medical costs exceed those payments. This segment provides medical, pharmacy, dental, and behavioral health benefits to approximately 26 million medical members through commercial employer plans, individual and family plans sold on the Affordable Care Act exchanges, Medicare Advantage plans, and Medicaid managed care contracts. When it rises — as it did sharply in 2024, reaching levels above 90 percent in some quarters due to elevated use in Medicare Advantage — the segment produces underwriting losses that can rapidly erase the value of the premium base. Under value-based care arrangements, Oak Street receives a fixed per-patient capitated payment from Medicare Advantage plans to provide comprehensive primary care services. Defenders argue that integration genuinely reduces friction, lowers costs, and improves health outcomes for patients who engage with the full CVS ecosystem. The scale of CVS's operations is genuinely staggering. CVS Health's current chapter is one of recalibration — a recognition that integration at this scale requires not just capital but sustained operational excellence across wildly different business functions, and that the financial markets will not indefinitely subsidize a strategy whose returns remain unclear. In Medicare Advantage specifically — the segment that caused CVS's 2024 financial crisis — competition is intense, with CMS reimbursement rates determining industry profitability in ways that no single insurer can fully control. The meta-competitive question facing CVS is whether vertical integration — its core strategic bet — actually creates sustainable competitive advantage or merely operational complexity. CVS Health's financial profile in fiscal year 2024 reflects the tension between extraordinary scale and profitability under pressure. The most immediate and financially damaging challenge is the deterioration of Aetna's Medicare Advantage underwriting results. Medicare Advantage plans, which had been a growth engine for the health insurance industry for years, encountered a reckoning as pent-up post-pandemic demand, higher acuity patient populations, and inadequate premium adjustments from the Centers for Medicare & Medicaid Services (CMS) compressed margins industry-wide. It reflects a genuine geographic coverage advantage that gives CVS the ability to serve as a point of prescription pickup, vaccination administration, acute care visit, and chronic disease monitoring at a scale that no competitor can match without decades of real estate investment. Caremark's PBM scale is equally formidable. While PBM regulatory risk is real, the sheer operational complexity of transitioning a large employer's pharmacy benefits to a new administrator creates inherent switching costs that benefit incumbents like Caremark. Brand recognition and consumer trust, built over sixty years of retail pharmacy presence in American communities, provide a softer but meaningful advantage in consumer-facing healthcare. Rather than opening new centers at maximum speed regardless of per-center economics, CVS is targeting markets where Medicare Advantage penetration is high, where Oak Street's value-based care model can capture the greatest risk adjustment upside, and where real estate and clinical staffing costs support attractive unit economics. CVS Health's trajectory over the next three to five years will be shaped by its success or failure in resolving three defining challenges: stabilizing Aetna's Medicare Advantage underwriting, managing pharmacy reimbursement economics through a period of structural compression, and demonstrating that Oak Street Health can scale to sufficient size to contribute meaningfully to enterprise profitability rather than consuming capital. The company has announced plans to reduce its Medicare Advantage membership — accepting lower enrollment in exchange for more appropriately priced plans — a strategy that trades near-term revenue scale for better underwriting economics. Value-based primary care for Medicare patients is both clinically effective — multiple studies demonstrate lower total cost of care and better patient outcomes — and financially attractive if scaled efficiently. Oak Street's model of serving Medicare Advantage populations, including Aetna members, creates a natural alignment between clinical and financial incentives.